Development of a novel noncompetitive antagonist of IL-1 receptor

Journal of Immunology

Volumn 180, Issue 10, 2008, Pages 6977-6987

  Quiniou, Christiane ^a   Sapieha, Przemyslaw ^a   Lahaie, Isabelle ^a   Hou, Xin ^a   Brault, Sonia ^a   Beauchamp, Martin ^a   Leduc, Martin ^a   Rihakova, Lenka ^a   Joyal, Jean Sebastien ^a   Nadeau, Sylvain ^a   Heveker, Nikolaus ^a   Lubell, William ^b   Sennlaub, Florian ^e   Gobeil Jr , Fernand ^d   Miller, Greg ^c   Pshezhetsky, Alexey V ^a   Chemtob, Sylvain ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITÉ DE SHERBROOKE   (Canada)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE I; PEPTIDE; PROTEIN SUBUNIT; RYTVELA; UNCLASSIFIED DRUG; 101.10 PEPTIDE; ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CELL PROLIFERATION; CONTACT DERMATITIS; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENTERITIS; HUMAN; HUMAN CELL; HYPERTHERMIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYMOCYTE; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DERMATITIS; DRUG ANTAGONISM; INFLAMMATION; MOLECULAR GENETICS; MOUSE MUTANT; PROTEIN TERTIARY STRUCTURE; RAT; SPRAGUE DAWLEY RAT; SYNTHESIS; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; DERMATITIS; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, INTERLEUKIN-1;

EID: 45549107664     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.10.6977     Document Type: Article

References (88)

1. McCulloch, C. A., G. P. Downey, and H. El-Gabalawy. 2006. Signalling platforms that modulate the inflammatory response: new targets for drug development. Nat. Rev. Drug Discov. 5: 864-876.
2. Kavanaugh, A. 2006. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. Adv. Ther. 23: 208-217.
3. Mce, J. B., M. J. Cork, F. S. di Giovine, G. W. Duff, and R. W. Groves. 2006. Interleukin-1: a key inflammatory mediator in psoriasis? Cytokine 33: 72-78.
4. Dower, S. K., J. E. Sims, T. H. Stanton, J. Slack, C. J. McMahan, M. A. Valentine, and K. Bomsztyk. 1990. Molecular heterogeneity of interleukin-1 receptors. Ann. NY Acad. Sci. 594: 231-239.
5. Dinarello, C. A., S. Gatti, and T. Bartfai. 1999. Fever: links with an ancient receptor. Curr. Biol. 9: R147-150.
6. Arend, W. P. 1993. Interleukin-1 receptor antagonist. Adv. Immunol. 54: 167-227.
7. Urban, J. D., W. P. Clarke, M. von Zastrow, D. E. Nichols, B. Kobilka, H. Weinstein, J. A. Javitch, B. L. Roth, A. Christopoulos, P. M. Sexton, et al. 2007. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320: 1-13.
8. Zhou, N., Z. Luo, J. Luo, X. Fan, M. Cayabyab, M. Hiraoka, D. Liu, X. Han, J. Pesavento, C. Z. Dong, et al. 2002. Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines. J. Biol. Client. 277: 17476-17485.
9. McDonnell, J. M., A. J. Beavil, G. A. Mackay, B. A. Jameson, R. Korngold, H. J. Gould, and B. J. Sutton. 1996. Structure based design and characterization of peptides that inhibit IgE binding to its high-affinity receptor. Nat. Struct. Biol. 3: 419-426.
10. Chalifour, R. J., R. W. McLaughlin, L. Lavoie, C. Morissette, N. Tremblay, M. Boule, P. Sarazin, D. Stea, D. Lacombe, P. Tremblay, and F. Gervais. 2003. Stereoselective interactions of peptide inhibitors with the 0-amyloid peptide. J. Biol. Chem. 278: 34874-34881.
11. Zhang, T. T, B. Cui, D. Z. Dai, and X. Y. Tang. 2005. Pharmacological efficacy of CPU 86017 on hypoxic pulmonary hypertension in rats: mediated by direct inhibition of calcium channels and antioxidant action, but indirect effects on the ET-I pathway. J. Cardiovasc. Pharmacol. 46: 727-734.
12. Peri, K. G., C. Quiniou, X. Hou, D. Abran, D. R. Varma, W. D. Lubell, and S. Chemtob. 2002. THG113: a novel selective FP antagonist that delays preterm labor. Semin. Perinatal. 26: 389-397.
13. Hebert, T. E., S. Moffett, J. P. Morello, T. P. Loisel, D. G. Bichet, C. Barret, and M. Bouvier. 1996. A peptide derived from a β2-adrenergic receptor transmem-brane domain inhibits both receptor dimerization and activation. J. Biol. Chem. 271: 16384-16392.
14. Gusic, R. J., M. Petko, R. Myung, J. William Gaynor, and K. J. Gooch. 2005. Mechanical properties of native and ex vivo remodeled porcine saphenous veins. J. Biomech. 38: 1770-1779.
15. Slingsby, C., O. A. Bateman, and A. Simpson. 1993. Motifs involved in protein-protein interactions. Mol. Biol. Rep. 17: 185-195.
16. Casadio, R., E. Frigimelica, P. Bossu, D. Neumann, M. U. Martin, A. Tagliabue, and D. Boraschi. 2001. Model of interaction of the IL-1 receptor accessory protein IL-lRAcP with the IL-lβ/IL-lR(I) complex. FEBS Lett. 499: 65-68.
17. Tan, D. C., R. M. Kini, S. D. Jois, D. K. Lim, L. Xin, and R. Ge. 2001. A small peptide derived from Flt-1 (VEGFR-1) functions as an angiogenic inhibitor. FEBS Lett. 494: 150-156.
18. Presland, J. 2005. Identifying novel modulators of G protein-coupled receptors via interaction at allosteric sites. Curr. Opin. Drug Discov. Devel. 8: 567-576.
19. Lazareno, S. 2004. Determination of allosteric interactions using radioligand-binding techniques. Methods Mol. Biol. 259: 29-46.
20. Murali, R., X. Cheng, A. Berezov, X. Du, A. Schon, E. Freire, X. Xu, Y. H. Chen, and M. I. Greene. 2005. Disabling TNF receptor signaling by induced confor-mational perturbation of tryptophan-107. Proc. Natl. Acad. Sci. USA 102: 10970-10975.
21. Anderson, M. E., B. A. Tejo, T. Yakovleva, and T. J. Siahaan. 2006. Characterization of binding properties of ICAM-1 peptides to LFA-1: inhibitors of T-cell adhesion. Chem. Biol. Drug Des. 68: 20-28.
22. Smeets, R. L., L. A. Joosten, O. J. Amtz, M. B. Bennink, N. Takahashi, H. Carlsen, M. U. Martin, W. B. van den Berg, and F. A. van de Loo. 2005. Soluble interIeukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interIeukin-1 receptor antagonist. Arthritis Rheum. 52: 2202-2211.
23. Labow, M., D. Shuster, M. Zetterstrom, P. Nunes, R. Terry, E. B. Cullinan, T. Bartfai, C. Solorzano, L. L. Moldawer, R. Chizzonite, and K. W. Mclntyre. 1997. Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J. Immunol. 159: 2452-2461.
24. Vigers, G. P., L. J. Anderson, P. Caffes, and B. J. Brandhuber. 1997. Crystal structure of the type-I interIeukin-1 receptor complexed with interIeukin-1β. Nature 386: 190-194.
25. Boeckmann, B., A. Bairoch, R. Apweiler, M. C. Blatter, A. Estreicher, E. Gasteiger, M. J. Martin, K. Michoud, C. O'Donovan, I. Phan, et al. 2003. The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res. 31: 365-370.
26. Rost, B., P. Fariselli, and R. Casadio. 1996. Topology prediction for helical transmembrane proteins at 86% accuracy. Protein Sci. 5: 1704-1718.
27. Kyte, J., and R. F. Doolittle. 1982. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157: 105-132.
28. Isbil-Buyukcoskun, N., G. Gulec, K. Ozluk, and I. H. Ulus. 2001. Central injection of captopril inhibits the blood pressure response to intracerebroventricular choline. Braz. J. Med. Biol. Res. 34: 815-820.
29. Brault, S., A. K. Martinez-Bermudez, A. M. Marrache, F. Gobeil, Jr., X. Hou, M. Beauchamp, C. Quiniou, G. Almazan, C. Lachance, J. Roberts, Jr., et al. 2003. Selective neuromicrovascular endothelial cell death by 8-Iso-prostaglandin F2a: possible role in ischemic brain injury. Stroke 34: 776-782.
30. Peterson, T. C., C. E. Cleary, A. M. Shaw, D. A. Malatjalian, and S. J. Veldhuyzen van Zanten. 2000. Therapeutic role for bismuth compounds in TNBS-induced colitis in the rat. Dig. Dis. Sci. 45: 466-473.
31. Strober, W. 1985. Animal models of inflammatory bowel disease: an overview. Dig. Dis. Sci. 30: 3S-10S.
32. Stein, J., J. Ries, and K. E. Barrett. 1998. Disruption of intestinal barrier function associated with experimental colitis: possible role of mast cells. Am. J. Physiol. 274: G203-G209.
33. Sandberg, J. O., D. L. Eizirik, and S. Sandier. 1997. IL-1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non-obese diabetic (NOD) mice. Clin. Exp. Immunol. 108: 314-317.
34. Zwerina, J., S. Hayer, M. Tohidast-Akrad, H. Bergmeister, K. Redlich, U. Feige, C. Dunstan, G. Kollias, G. Steiner, J. Smolen, and G. Schett. 2004. Single and combined inhibition of tumor necrosis factor, interIeukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 50: 277-290.
35. Krawisz, J. E., P. Sharon, and W. F. Stenson. 1984. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity: assessment of inflammation in rat and hamster models. Castroenlerology 87: 1344-1350.
36. Nadeau, S., and S. Rivest. 2002. Endotoxemia prevents the cerebral inflammatory wave induced by intraparenchymal lipopolysaccharide injection: role of glu-cocorticoids and CD14. J. Immunol. 169: 3370-3381.
37. Tomonari, K. 1988. A rat antibody against a structure functionally related to the mouse T-cell receptor/T3 complex. Immunogenetics 28: 455-458.
38. Rauschmayr, T., R. W. Groves, and T. S. Kupper. 1997. Keratinocyte expression of the type 2 interIeukin 1 receptor mediates local and specific inhibition of interIeukin 1-mediated inflammation. Proc. Nail. Acad. Sci. USA 94: 5814-5819.
39. Wamberg, S., N. C. Sandgaard, and P. Bie. 2002. Simultaneous determination of total body water and plasma volume in conscious dogs by the indicator dilution principle. J Nutr. 132: 1711S-1713S.
40. Dombrowicz, D., V. Flamand, I. Miyajima, J. V. Ravetch, S. J. Galli, and J. P. Kinet. 1997. Absence of FceRI a chain results in upregulation of FcyRIII-dependent mast cell degranulation and anaphylaxis: evidence of competition between FceRI and FcyRIII for limiting amounts of FcR fi and y chains. J. Clin. Invest. 99: 915-925.
41. Gobeil, F., A. Fortier, T. Zhu, M. Bossolasco, M. Leduc, M. Grandbois, N. Heveker, G. Bkaily, S. Chemtob, and D. Barbaz. 2006. G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. Can. J. Physiol. Pharmacol. 84: 287-297.
42. Fan, L., W. V. Yotov, T. Zhu, L. Esmailzadeh, J. S. Joyal, F. Sennlaub, N. Heveker, S. Chemtob, and G. E. Rivard. 2005. Tissue factor enhances pro-tease-activated receptor-2-mediated factor Vila cell proliferative properties. J. Thromb. Haemost. 3: 1056-1063.
43. Li, D. Y., P. Hardy, D. Abran, A. K. Martinez-Bermudez, A. M. Guerguerian, M. Bhattacharya, G. Almazan, R. Menezes, K. G. Peri, D. R. Varma, and S. Chemtob. 1997. Key role for cyclooxygenase-2 in PGE2 and PGF2ot receptor regulation and cerebral blood flow of the newborn. Am. J. Physiol. 273: R1283-R1290.
44. Banks, W. A. 1999. Characterization of interIeukin-la binding to mouse brain endothelial cells. J. Pharmacol. Exp. Ther. 291: 665-670.
45. Marrache, A. M., F. Gobeil, Jr., S. G. Bemier, J. Stankova, M. Rola-Pleszczynski, S. Choufani, G. Bkaily, A. Bourdeau, M. G. Sirois, A. Vazquez-Tello, et al. 2002. Proinflammatory gene induction by platelet-activating factor mediated via its cognate nuclear receptor. J. Immunol. 169: 6474-6481.
46. Takeuchi, M., S. Nagai, H. Nakada, H. Aung, N. Satake, H. Kaneshima, and T. Izumi. 1992. Characterization of IL-1 inhibitory factor released from human alveolar macrophages as IL-I receptor antagonist. Clin. Exp. Immunol. 88: 181-187.
47. Howe, R. C., J. W. Lowenthal, and H. R. MacDonald. 1986. Role of interIeukin I in early T cell development: Lyt-2-L3T4-ihymocytes bind and respond in vitro to recombinant IL 1. J. Immunol. 137: 3195-3200.
48. Cox, G. W., B. J. Mathieson, S. L. Giardina, and L. Varesio. 1990. Characterization of IL-2 receptor expression and function on murine macrophases. J. Immunol. 145: 1719-1726.
49. Gao, Z. G., S. K. Kim, A. P. Ijzerman, and K. A. Jacobson. 2005. Allosteric modulation of the adenosine family of receptors. Mini. Rev. Med. Chem. 5: 545-553.
50. Lazarus, M. 2006. The differential role of prostaglandin E2 receptors EP3 and EP4 in regulation of fever. Mol. Nutr. Food Res. 50: 451-455.
51. Romanovsky, A. A., M. C. Almeida, D. M. Aronoff, A. I. Ivanov, J. P. Konsman, A. A. Steiner, and V. F. Turek. 2005. Fever and hypothermia in systemic inflammation: recent discoveries and revisions. From. Biosci. 10: 2193-2216.
52. Boie, Y., R. Stocco, N. Sawyer, D. M. Slipetz, M. D. Ungrin, F. Neuschafer-Rube, G. P. Puschel, K. M. Metiers, and M. Abramovitz. 1997. Molecular cloning and characterization of the four rat prostaglandin E2 prosta-noid receptor subtypes. Eur. J. Pharmacol. 340: 227-241.
53. Gardiner, S. M., P. A. Kemp, J. E. March, J. Woolley, and T. Bennett. 1998. The influence of antibodies to TNF-α and IL-1β on haemodynamic responses to the cytokines, and to lipopolysaccharide, in conscious rats. Br. J. Pharmacol. 125: 1543-1550.
54. Rogler, G., and T. Andus. 1998. Cytokines in inflammatory bowel disease. World J. Surg. 22: 382-389.
55. Maeda, S., L. C. Hsu, H. Liu, L. A. Bankston, M. Iimura, M. F. Kagnoff, L. Eckmann, and M. Karin. 2005. Nod2 mutation in Crohn's disease potentiates NF-κB activity and IL-1β processing. Science 307: 734-738.
56. Corsini, E., and C. L. Galli. 1998. Cytokines and irritant contact dermatitis. Toxicol. Lett. 102-103: 277-282.
57. Galvez, J., M. Garrido, M. E. Rodriguez-Cabezas, I. Ramis, F. S. de Medina, M. Merlos, and A. Zarzuelo. 2003. The intestinal anti-inflammatory activity of UR-I2746S on reactivated experimental colitis is mediated through downregu-lation of cytokine production. Inftamm. Bowel Dis. 9: 363-371.
58. Ha, H. Y., Y. Kim, Z. Y. Ryoo, and T. Y. Kim. 2006. Inhibition of the TPA-induced cutaneous inflammation and hyperplasia by EC-SOD. Biochem. Biophys. Res. Commun. 348: 450-458.
59. Carter, D. B., M. R. Deibel, Jr., C. J. Dunn, C. S. Tomich, A. L. Laborde, J. L. Slightom, A. E. Berger, M. J. Bienkowski, F. F. Sun, R. N. McEwan, et al. 1990. Purification, cloning, expression and biological characterization of an interIeukin-1 receptor antagonist protein. Nature 344: 633-638.
60. Kenakin, T., and O. Onaran. 2002. The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol. Sci. 23: 275-280.
61. Kenakin, T. 2004. Allosteric modulators: the new generation of receptor antagonist. Mol. Interv. 4: 222-229.
62. Kenakin, T. 2004. G-protein coupled receptors as allosteric machines. Receptors Channels 10: 51-60.
63. Kenakin, T. 2004. Principles: receptor theory in pharmacology. Trends Pharmacol. Sci. 25: 186-192.
64. Kenakin, T. 2004. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol. Pharmacol. 65: 2-11.
65. Kenakin, T. 2005. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat. Rev. Drug Discov. 4: 919-927.
66. Gonzalez-Ruiz, D., and H. Gohlke. 2006. Targeting protein-protein interactions with small molecules: challenges and perspectives for computational binding epitope detection and ligand finding. Curr. Med. Chem. 13: 2607-2625.
67. May, L. T., K. Leach, P. M. Sexton, and A. Christopoulos. 2007. Allosteric modulation of g protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47: 1-51.
68. Miedlich, S. U., L. Gama, K. Seuwen, R. M. Wolf, and G. E. Breitwieser. 2004. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J. Biol. Chem. 279: 7254-7263.
69. Kenakin, T., S. Jenkinson, and C. Watson. 2006. Determining the potency and molecular mechanism of action of insurmountable antagonists. J. Pharmacol. Exp. Ther. 319: 710-723.
70. Lukong, K. E., M. A. Elsliger, J. S. Mort, M. Potier, and A. V. Pshezhetsky. 1999. Identification of UDP-N-acetylgIucosamine-phosphotransferase- binding sites on the lysosomal proteases, cathepsins A, B, and D. Biochemistry 38: 73-80.
71. Xie, Y., S. M. Massa, S. E. Ensslen-Craig, D. L. Major, T. Yang, M. A. Tisi, V. D. Derevyanny, W. O. Runge, B. P. Mehta, L. A. Moore, et al. 2006. Protein-tyrosine phosphatase (FTP) wedge domain peptides: a novel approach for inhibition of PTP function and augmentation of protein-tyrosine kinase function. J. Biol. Chem. 281: 16482-16492.
72. Ehlert, F. J. 2005. Analysis of allosterism in functional assays. J. Pharmacol. Exp. Ther. 315:740-754.
73. Koshland, D. E., Jr. 1998. Conformational changes: how small is big enough? Nat. Med. 4: 1112-1114.
74. Christopoulos, A. 2002. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug. Discov. 1: 198-210.
75. Christopoulos, A., L. T. May, V. A. Avlani, and P. M. Sexton. 2004. G-protein-coupled receptor allosterism: the promise and the problem(s). Biochem. Soc. Trans 32: 873-877.
76. + in cultured rat embryonic hippocampal neurons using a fluorescence microplate reader: potential application to biomolecular screening. J. Pharmacol. Toxicol. Methods 49: 81-87.
77. Maillet, E. L., N. Pellegrini, C. Valant, B. Bucher, M. Hibert, J. J. Bourguignon, and J. L. Galzi. 2007. A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. FASEB J. 21: 2124-2134.
78. Rodriguez, A. L., Y. Nong, N. K. Sekaran, D. Alagille, G. D. Tamagnan, and P. J. Conn. 2005. A close structural analog of 2-methyl-6-(phenylethynyl)- pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol. Pharmacol. 68: 1793-1802.
79. Lysikova, M, Z. Havlas, and S. Tucek. 2001. Interactions between allosteric modulators and 4-DAMP and other antagonists at muscarinic receptors: potential significance of the distance between the N and carboxyl C atoms in the molecules of antagonists. Neurochem. Res. 26: 383-394.
80. Litschig, S., F. Gasparini, D. Rueegg, N. Stoehr, P. J. Flor, I. Vranesic, L. Prezeau, J. P. Pin, C. Thomsen, and R. Kuhn. 1999. CPCCOEt, a noncom-petitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol. Pharmacol. 55: 453-461.
81. Neurath, M. F. 2000. Immunotherapy of inflammatory bowel diseases: current concepts and future perspectives. Arch. Immunol. Ther. Exp. 48: 81-84.
82. Kim, H. S., and A. Berstad. 1992. Experimental colitis in animal models. Scand. J. Gastroenterol. 27: 529-537.
83. Hauser, C., J. H. Saurat, A. Schmitt, F. Jaunin, and J. M. Dayer. 1986. Interleukin 1 is present in normal human epidermis. J. Immunol. 136: 3317-3323.
84. Kondo, S., B. P. Barna, T. Morimura, J. Takeuchi, J. Yuan, A. Akbasak, and G. H. Barnett. 1995. Interleukin-1 β-converting enzyme mediates cisplatin-induced apoptosis in malignant glioma cells. Cancer Res. 55: 6166-6171.
85. Kondo, S., S. Pastore, H. Fujisawa, G. M. Shivji, R. C. McKenzie, C. A. Dinarello, and D. N. Sauder. 1995. Interleukin-1 receptor antagonist suppresses contact hypersensitivity. J. Invest. Dermatol. 105: 334-338.
86. Zhu, F., J. Qian, G. Pan, and S. Quan. 1998. The effect of interIeukin-1 β interIeukin-8 in the pathogenesis of experimental colitis and evaluation of interIeukin-1 receptor antagonist therapy. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 20: 388-394.
87. Ricci, S., G. Macchia, P. Ruggiero, T. Maggi, P. Bossu, L. Xu, D. Medaglini, A. Tagliabue, L. Hammarstrom, G. Pozzi, and D. Boraschi. 2003. In vivo mucosal delivery of bioactive human interIeukin 1 receptor antagonist produced by Streptococcus gordonii. BMC Biotechnol. 3: 15.
88. Matthews, J. C. 1993. Fundamentals of Receptor, Enzyme, and Transport Kinetics, 1st Ed. CRC Press, Boca Raton, FL, pp. 63-94.